| 引用本文: | 齐知超,陈金玲,白青春,王欢,拉喜那木吉拉.基于网络药理学和细胞验证探讨蒙药冬青叶对肺功能异常治疗机制研究[J].中国现代应用药学,2026,43(18):86-96. |
| QiZhichao,chen jinling,bai qingchun,wang huan,Laxinamujila.Study on the Therapeutic Mechanism of Mongolian Medicine Rhododendron micranthum Turcz. Leaf in Treating Abnormal Plumonary Function Based on Network Pharmacology and Cellular Verification[J].Chin J Mod Appl Pharm(中国现代应用药学),2026,43(18):86-96. |
|
| 摘要: |
| 目的:基于网络药理学预测蒙药冬青叶活性成分组合防治肺功能异常的作用机制,并用体外实验验证。方法:通过中药系统药理学数据库与分析平台(TCMSP)和Pubchem数据库筛选蒙药冬青叶活性成分,运用GeneCards数据库检索“肺功能异常”相关靶点,提取交集靶点;用String数据库构建PPI网络,DAVID数据库进行GO及KEGG通路富集分析。以SD大鼠为研究对象,通过腹腔注射“野百合碱”+“幽门结扎”术建立肺功能异常病症模型,HE染色法及Masson染色法检测大鼠肺组织病理学改变;肺功能检测仪检测肺功能变化;能量代谢仪检测代谢情况。用模型大鼠血清诱导肺动脉平滑肌细胞(PASMC)建立肺功能异常致肺动脉平滑肌细胞异常增殖模型,CCK-8法检测细胞存活率,EDU法检测细胞增殖能力,Western blotting 法检测细胞中AKT、P-AKT、mTOR、P-mTOR、EGFR、PI3K蛋白的表达。结果:1.网络药理学结果表明,蒙药冬青叶的主要核心成分(槲皮素、丁香酸、莨菪亭、东莨菪苷)可能通过抑制AKT、P-AKT、mTOR、P-mTOR、EGFR、PI3K蛋白表达而起到治疗肺功能异常的作用。2.动物实验结果表明,与正常组比较模型组大鼠CO2量显著降低,模型组FVC、ERV(P<0.05)水平显著降低;HE染色与masson染色结果均表明,模型组PASMC细胞增多,血管壁增厚。3.细胞实验结果表明,与对照组相比,模型组显著升高了PASMC的P-AKT、P-mTOR、EGFR和PI3KI;与模型组比较,治疗组P-AKT、P-mTOR、EGFR和PI3KI蛋白水平显著降低。结论:首先通过网络药理学得知,蒙药冬青叶治疗肺功能异常的机制可能与P-AKT、P-mTOR、EGFR、PI3K等蛋白有关。其次通过动物实验发现,“幽门结扎+ 野百合碱”能够成功建立肺功能异常病症模型。最后通过细胞实验发现,蒙药冬青叶核心成分组合可通过降低P-AKT、P-mTOR、EGFR、PI3K蛋白的表达水平,抑制模型大鼠血清诱导的PASMC增殖,从而发挥治疗肺功能异常的作用。 |
| 关键词: 蒙药冬青叶 肺功能异常 网络药理学 分子对接 实验验证 |
| DOI: |
| 分类号: |
| 基金项目:国家自然科学基金项目;2025年内蒙古医科大学博士启动基金项目 |
|
| Study on the Therapeutic Mechanism of Mongolian Medicine Rhododendron micranthum Turcz. Leaf in Treating Abnormal Plumonary Function Based on Network Pharmacology and Cellular Verification |
|
QiZhichao1, chen jinling, bai qingchun, wang huan2, Laxinamujila
|
|
1.INNER MCNGGOLIA MINZU UNIVERSITY;2.Inner Mongolia Medical University
|
| Abstract: |
| ABSTRACT
Objective: To predict the mechanism of active ingredient combinations from Mongolian medicine Rhododendron dauricum Leaf against abnormal pulmonary function using network pharmacology, and to verify the mechanism through in vitro experiments.
Methods:
The active ingredients of Rhododendron dauricum Leaf , a Mongolian medicine, were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and the PubChem database. Targets related to “abnormal pulmonary function” were retrieved from the GeneCards database, and the intersecting targets were extracted. A protein–protein interaction (PPI) network was constructed using the STRING database, and Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed via the DAVID database.
Sprague–Dawley (SD) rats were used as experimental animals. A rat model of abnormal pulmonary function was established by intraperitoneal injection of monocrotaline combined with pylorus ligation. Pathological changes in rat lung tissues were examined by hematoxylin–eosin (HE) staining and Masson’s trichrome staining. Pulmonary function was measured using a pulmonary function analyzer, and metabolic status was detected using an energy metabolism instrument.
Abnormal proliferation of pulmonary artery smooth muscle cells (PASMCs) induced by abnormal pulmonary function was modeled by stimulating PASMCs with serum from model rats. Cell viability was determined using the Cell Counting Kit-8 (CCK-8) assay, and cell proliferation was evaluated using the 5-ethynyl-2′-deoxyuridine (EDU) incorporation assay. The protein expression levels of AKT, P-AKT, mTOR, P-mTOR, EGFR, and PI3K in cells were detected by Western blotting.
Results
1.Network pharmacology results showed that the main core components of Mongolian medicine Ilex chinensis (quercetin, syringic acid, scopoletin, scopolin) may exert therapeutic effects on abnormal pulmonary function by inhibiting the protein expression of AKT, P-AKT, mTOR, P-mTOR, EGFR, and PI3K.
2.Animal experiment results demonstrated that compared with the normal group, the model group exhibited significantly decreased CO? production, as well as markedly reduced levels of forced vital capacity (FVC) and expiratory reserve volume (ERV) (P?<?0.05). HE staining and Masson’s trichrome staining both revealed increased pulmonary artery smooth muscle cells (PASMCs) and thickened vascular walls in the model group.
3.Cell experiment results indicated that, compared with the control group, the model group showed significantly elevated levels of phosphorylated AKT (P-AKT), phosphorylated mTOR (P-mTOR), EGFR, and PI3K in PASMCs. In contrast, compared with the model group, the treatment group displayed significantly decreased protein levels of P-AKT, P-mTOR, EGFR, and PI3K.
Conclusion:
1.Network pharmacology analysis revealed that the mechanism by which Mongolian medicine Ilex chinensis treats abnormal pulmonary function may be associated with proteins including P-AKT, P-mTOR, EGFR, and PI3K.
2.Animal experiments further confirmed that the combination of pylorus ligation and monocrotaline can successfully establish a rat model of abnormal pulmonary function.
3.Cell experiments demonstrated that the core component combination of Ilex chinensis can inhibit the proliferation of pulmonary artery smooth muscle cells (PASMCs) induced by serum from model rats by downregulating the protein expression of P-AKT, P-mTOR, EGFR, and PI3K, thereby exerting a therapeutic effect on abnormal pulmonary function. |
| Key words: mongolia medicine Rhododendron dauricum Leaf abnormal pulmonary function network pharmacology molecular docking experimental verification |